Tokyo (JCN) Dec 27, 2005 - Daiichi Sankyo has announced that its wholly owned subsidiary Daiichi Pharmaceutical has won the lawsuit against Mylan Pharmaceuticals. Specifically, the US Court of Appeals for the Federal Circuit has affirmed the validity of US patent (No. 5,053,407) on levofloxacin, a broad spectrum synthetic antibacterial agent held by Daiichi. Consequently, Mylain is prohibited from producing any generic version of levofloxacin until Daiichi's patent expires.
